Literature DB >> 12781523

Neutrophil granulocytes--Trojan horses for Leishmania major and other intracellular microbes?

Tamás Laskay1, Ger van Zandbergen, Werner Solbach.   

Abstract

Polymorphonuclear neutrophil granulocytes (PMNs) possess numerous effector mechanisms to kill ingested pathogens as the first line of defence. However, several microorganisms evade intracellular killing in neutrophils, survive and retain infectivity. There is increasing evidence that several pathogens even multiply within neutrophils. Taking Leishmania major as a prototypic intracellular pathogen, we suggest an evasion strategy that includes the manipulation of PMNs in such a way that the pathogens are able to use the granulocytes as host cells. The ability to survive and maintain infectivity in PMNs subsequently enables these organisms to establish productive infection. These organisms can use granulocytes as Trojan horses before they enter their definitive host cells, the macrophages.

Entities:  

Mesh:

Year:  2003        PMID: 12781523     DOI: 10.1016/s0966-842x(03)00075-1

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN: 0966-842X            Impact factor:   17.079


  86 in total

1.  Infection of neutrophil granulocytes with Leishmania major activates ERK 1/2 and modulates multiple apoptotic pathways to inhibit apoptosis.

Authors:  Arup Sarkar; Eresso Aga; Uta Bussmeyer; Asima Bhattacharyya; Sonja Möller; Lars Hellberg; Martina Behnen; Werner Solbach; Tamás Laskay
Journal:  Med Microbiol Immunol       Date:  2012-06-03       Impact factor: 3.402

2.  Persistence of Systemic Murine Norovirus Is Maintained by Inflammatory Recruitment of Susceptible Myeloid Cells.

Authors:  Jacob A Van Winkle; Bridget A Robinson; A Mack Peters; Lena Li; Ruth V Nouboussi; Matthias Mack; Timothy J Nice
Journal:  Cell Host Microbe       Date:  2018-11-01       Impact factor: 21.023

3.  Coxiella burnetii inhibits apoptosis in human THP-1 cells and monkey primary alveolar macrophages.

Authors:  Daniel E Voth; Dale Howe; Robert A Heinzen
Journal:  Infect Immun       Date:  2007-07-02       Impact factor: 3.441

Review 4.  Understanding the multiple functions of Gr-1(+) cell subpopulations during microbial infection.

Authors:  Charlotte E Egan; Woraporn Sukhumavasi; Allison L Bierly; Eric Y Denkers
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

5.  Anaplasma phagocytophilum delay of neutrophil apoptosis through the p38 mitogen-activated protein kinase signal pathway.

Authors:  Kyoung-Seong Choi; Joon Tae Park; J Stephen Dumler
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

6.  Circulating and bone marrow myeloid cells containing Leishmania amastigotes in a case of advanced canine leishmaniosis.

Authors:  Ioannis L Oikonomidis; Theodora K Tsouloufi; Mathios E Mylonakis; Dimitra Psalla; Nectarios Soubasis; Timoleon Rallis; Maria Kritsepi-Konstantinou
Journal:  J Vet Diagn Invest       Date:  2019-07-05       Impact factor: 1.279

Review 7.  Macrophages clean up: efferocytosis and microbial control.

Authors:  Constance J Martin; Kristen N Peters; Samuel M Behar
Journal:  Curr Opin Microbiol       Date:  2013-12-05       Impact factor: 7.934

Review 8.  Molecular epidemiology for vector research on leishmaniasis.

Authors:  Hirotomo Kato; Eduardo A Gomez; Abraham G Cáceres; Hiroshi Uezato; Tatsuyuki Mimori; Yoshihisa Hashiguchi
Journal:  Int J Environ Res Public Health       Date:  2010-03-05       Impact factor: 3.390

9.  Kinetic analysis of ex vivo human blood infection by Leishmania.

Authors:  Inmaculada Moreno; Mercedes Domínguez; Darío Cabañes; Carmen Aizpurua; Alfredo Toraño
Journal:  PLoS Negl Trop Dis       Date:  2010-07-13

10.  The NOD/RIP2 pathway is essential for host defenses against Chlamydophila pneumoniae lung infection.

Authors:  Kenichi Shimada; Shuang Chen; Paul W Dempsey; Rosalinda Sorrentino; Randa Alsabeh; Anatoly V Slepenkin; Ellena Peterson; Terence M Doherty; David Underhill; Timothy R Crother; Moshe Arditi
Journal:  PLoS Pathog       Date:  2009-04-10       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.